Placing Novel, Fixed-Dose Dual Bronchodilators within the nice Guidelines for Chronic Obstructive Pulmonary Disease -Reflections on the Past, Present and Future
Journal Title: Archives of Pulmonology and Respiratory Care - Year 2015, Vol 1, Issue 1
Abstract
The current National Institute for Health and Care Excellence (NICE) chronic obstructive pulmonary disease (COPD) guidelines were updated in 2010, reflecting clinical evidence available at that time. Since the guidelines were written, a growing body of evidence has demonstrated enhanced Bronchodilation with LABA/LAMA in fixed-dose combinations (FDCs) versus single component agents (the standard of care) in moderate to severe COPD. Studies to date indicate that the indacaterol/glycopyrronium (QVA149) and umeclinidium/vilanterol (UMEC/VI) can optimize Bronchodilation and may lead to improvements in patient-reported outcomes beyond lung function. The evidence for LABA/LAMA FDC, in particular glycopyrronium/indacaterol, and also umeclidinium/vilanterol, supported by meta-analysis, shows that dual Bronchodilation provides superior efficacy compared with LAMA monotherapy (glycopyrronium or tiotropium), and suggests the appropriateness of progression to LABA/LAMA combinations after LAMA mono therapy rather than escalation to LABA/ICS in patients with persistent breathlessness. The debate regarding the benefits and risks of LABA/ICS is on-going, with data now more firmly showing an association with inhaled ICS use and pneumonia. In patients with moderate or severe airflow obstruction and no history of exacerbations in the past year, randomised data showed that glycopyrronium/indacaterol was superior to LABA/ICS in improving lung function and breathlessness score. How to quantify the benefits of LABA/LAMA FDC over Mono therapy will be an ongoing debate, and consideration of other parameters such as a responder analysis of the proportion of patients that did achieve a threshold, may be better suited to establish clinically relevant differences between active agents and placebo. This review highlights the need to consider revisions to the current NICE COPD guidelines to reflect the recently published evidence demonstrating a role for LABA/LAMA FDC in the treatment of moderate to severe COPD.
Authors and Affiliations
O’Reilly John
Keywords
Related Articles
- EP ID EP340212
- DOI 10.17352/aprc.000001
- Views 76
- Downloads 0
Interventional Pulmonology in 2015: A Survey of Practice Patterns and Future Directions of this Emerging Field
Background: Interventional Pulmonology (IP) training through formal fellowship programs have become increasingly popular over the last several years. There is a dearth of data on the current practice of IP in the United...
Clinical and Functional Outcomes of Sensitizer-Induced Asthma in Bakers and Cotton Workers after Removal from Exposure
Introduction: Sensitizer-induced occupational asthma (OA) has significant health and socioeconomic outcomes in affected subjects. Objective: To evaluate clinical and functional outcomes of sensitizer-induced OA in baker...
Spontaneous Haemomediastinum and Fatal Haemoperitoneum in woman with Vascular Ehlers-Danlos Syndrome
Vascular Ehlers-Danlos Syndrome (EDS) presents with fragility of blood vessels, with high incidence of fatal hemorrhages in middle-age adults. We present a 38-year old female with vascular EDS presented to the emergency...
Ticarcillin Hypersusceptibility in Pseudomonas Aeruginosa in Cystic Fibrosis
Background: A subpopulation of Pseudomonas aeruginosa (PsA) exists in cystic fibrosis (CF) patients that is hypersusceptible to ticarcillin, a carboxypenicillin, in vitro (Tichs strain) defined as a minimum inhibitory co...
Review of the literature about Thymic Carcinomas
Background: Thymic carcinomas (TC) are rare tumors with challenging diagnosis and management. We aimed to describe the clinical and microscopic characteristics of TC through a literature review. Results: 82 articles and...